Based in Toronto, Canada, Apotex also operates in the United States, Mexico and India. The company employs close to 8,000 people worldwide in manufacturing, R&D and commercial operations. Its Apobiologix division focuses on biosimilars development.
Here are some of Apotex’s most recent endeavors with the biggest impact:
WASHINGTON, DC (August 6, 2020) — Developers of generic and biosimilar medicines support diversification of the pharmaceutical supply chain and are working with policymakers to add to our significant manufacturing presence in the United States. The generic industry already makes tens of billions of doses of safe, effective and affordable medicines here in America each year and drafted recommendations to increase that production capacity – “A Blueprint for Enhancing the Security of the U.S.
The U.S. generics and biosimilars industry, makers of 90% of our nation's prescription medicines, has a plan to "#SecureOurMeds." We already produce billions of doses of medicine right here in America, and our plan ensures continued patient access through #COVID and beyond.
Find out more about our path forward: https://accessiblemeds.org/blueprint
Steve Giuli works at Apotex as Vice President, Government Affairs & Trade Relations. Steve is proud to be a part of the generic drug industry that saves and improves patients' lives. AAM is recognizing dedicated people like Steve and his peers across the generics and biosimilars industry who show up each day for U.S. patients.
AAM’s Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain and documents like it provide lawmakers with the ingredients for achieving a legislative goal.
Last week the U.S. Department of Health and Human Services announced a grant worth up to $812 million for a public-private partnership to manufacture COVID-related medicines in the United States.
WASHINGTON, DC (June 2, 2020) — The COVID-19 crisis exposed many shortcomings in our health care system’s ability to respond to a pandemic. At the same time, many parts of that same system — including the supply chain for the vast majority of generic medicines — demonstrated extraordinary resiliency in the face of unprecedented stresses.
Sweta Modha works as a Packaging Technician at Apotex. AAM is recognizing dedicated people like Sweta who show up each day for America's patients. She is proud to work to ensure the supply chain continuity of essential medicines during the #COVID19 public health emergency.
AAM Board Chair Alok Sonig at Lupin: "We are working night and day globally across our manufacturing footprint to make sure our essential employees are able to come to our sites... and despite the challenges are able to make the product that is critically needed globally and we are doing that." #covid19
The COVID-19 (Coronavirus) pandemic is reminding all of us how much health matters in our families, our communities and our nation. The Association for Accessible Medicines is committed to the secure and consistent supply of critical pharmaceuticals that support good health and the recharging of the U.S. economy.